Zacks Research Comments on Danaher’s Q3 Earnings (NYSE:DHR)

Danaher Corporation (NYSE:DHR) – Analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Danaher in a research note issued on Tuesday, August 12th. Zacks Research analyst R. Department now expects that the conglomerate will earn $1.71 per share for the quarter, down from their prior estimate of $1.79. The consensus estimate for Danaher’s current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Danaher’s Q4 2025 earnings at $2.37 EPS, FY2025 earnings at $7.75 EPS, Q2 2026 earnings at $1.93 EPS, Q3 2026 earnings at $2.00 EPS, Q4 2026 earnings at $2.60 EPS, FY2026 earnings at $8.52 EPS, Q1 2027 earnings at $2.07 EPS and FY2027 earnings at $9.27 EPS.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. During the same quarter in the prior year, the company posted $1.72 EPS. The business’s revenue was up 3.4% on a year-over-year basis.

Several other equities research analysts have also weighed in on DHR. Barclays reaffirmed an “overweight” rating and issued a $225.00 target price (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. TD Cowen upped their target price on shares of Danaher from $240.00 to $248.00 and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Evercore ISI lowered their target price on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Argus lowered their target price on shares of Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $247.61.

Danaher Trading Up 0.6%

Shares of DHR stock opened at $210.43 on Wednesday. Danaher has a 52-week low of $171.00 and a 52-week high of $279.90. The stock has a market cap of $150.68 billion, a price-to-earnings ratio of 44.77, a P/E/G ratio of 2.92 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm has a fifty day moving average of $199.64 and a 200-day moving average of $200.12.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of DHR. Bank Pictet & Cie Europe AG boosted its stake in shares of Danaher by 22.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate’s stock valued at $44,241,000 after purchasing an additional 35,730 shares during the last quarter. Cohen & Steers Inc. boosted its stake in shares of Danaher by 5.4% in the 4th quarter. Cohen & Steers Inc. now owns 1,177 shares of the conglomerate’s stock valued at $270,000 after purchasing an additional 60 shares during the last quarter. Mariner LLC boosted its stake in shares of Danaher by 36.2% in the 4th quarter. Mariner LLC now owns 311,375 shares of the conglomerate’s stock valued at $71,477,000 after purchasing an additional 82,725 shares during the last quarter. CreativeOne Wealth LLC raised its position in shares of Danaher by 16.1% in the 4th quarter. CreativeOne Wealth LLC now owns 1,790 shares of the conglomerate’s stock valued at $411,000 after acquiring an additional 248 shares during the period. Finally, Belpointe Asset Management LLC raised its position in shares of Danaher by 2.4% in the 4th quarter. Belpointe Asset Management LLC now owns 8,847 shares of the conglomerate’s stock valued at $2,031,000 after acquiring an additional 209 shares during the period. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.